Ranbaxy settles down 9 pc on the bourses
Shares of pharma major Ranbaxy Laboratories settled down nine per cent on the bourses, amid reports that the Australian health regulator has undertaken a further review of products of the Indian pharma major.
By PTI |
MUMBAI: Shares of pharma major Ranbaxy Laboratories settled down nine per cent on the bourses, amid reports that the Australian health regulator has undertaken a further review of products of the Indian pharma major.
Shares of Ranbaxy settled down 9.27 per cent at Rs 144.40. During the market hours the scrip touched its 52 week low of Rs 140.25, down 11.87 per cent.
Similar, movement was seen on the National Stock Exchange where the scrip settled down 9.43 per cent at Rs 144.05. It touched an intra-day low of Rs 140.15, down 11.88 per cent.
A total of over 1.40 crore shares of Ranbaxy changed hands on both the bourses.
On Wednesday, the Sydney Morning Herald noted that the Australian administration, Therapeutic Goods Administration, has undertaken a further review of products and testing to verify that products produced from this facility meet the quality standards expected.
It was reviewing latest information from the FDA and has sought more details concerning products sold in Australia, the paper said.
Meanwhile, Ranbaxy Labs today has received the approval of US health regulator, for Quinapril Hydrochloride and Hydrochlorothiazide tablets, used in treatment of high blood pressure in different strengths.
Shares of Ranbaxy settled down 9.27 per cent at Rs 144.40. During the market hours the scrip touched its 52 week low of Rs 140.25, down 11.87 per cent.
Similar, movement was seen on the National Stock Exchange where the scrip settled down 9.43 per cent at Rs 144.05. It touched an intra-day low of Rs 140.15, down 11.88 per cent.
A total of over 1.40 crore shares of Ranbaxy changed hands on both the bourses.
On Wednesday, the Sydney Morning Herald noted that the Australian administration, Therapeutic Goods Administration, has undertaken a further review of products and testing to verify that products produced from this facility meet the quality standards expected.
It was reviewing latest information from the FDA and has sought more details concerning products sold in Australia, the paper said.
ADVERTISEMENT
Meanwhile, Ranbaxy Labs today has received the approval of US health regulator, for Quinapril Hydrochloride and Hydrochlorothiazide tablets, used in treatment of high blood pressure in different strengths.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
